EP0745596B1 - Hetero aromatische oxazole und deren verwendung - Google Patents

Hetero aromatische oxazole und deren verwendung Download PDF

Info

Publication number
EP0745596B1
EP0745596B1 EP95940466A EP95940466A EP0745596B1 EP 0745596 B1 EP0745596 B1 EP 0745596B1 EP 95940466 A EP95940466 A EP 95940466A EP 95940466 A EP95940466 A EP 95940466A EP 0745596 B1 EP0745596 B1 EP 0745596B1
Authority
EP
European Patent Office
Prior art keywords
compound
fluorophenyl
cyclohexyl
pharmaceutically acceptable
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP95940466A
Other languages
English (en)
French (fr)
Other versions
EP0745596A1 (de
EP0745596A4 (de
Inventor
Junichi Central Pharm. Research Institute Haruta
Hiromasa Central Pharm. Research Inst. Hashimoto
Mutsuyoshi Cent. Pharm. Research Inst. Matsushita
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Japan Tobacco Inc
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27468109&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP0745596(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of EP0745596A1 publication Critical patent/EP0745596A1/de
Publication of EP0745596A4 publication Critical patent/EP0745596A4/de
Application granted granted Critical
Publication of EP0745596B1 publication Critical patent/EP0745596B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/30—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by doubly-bound oxygen atoms
    • C07C233/31—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by doubly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32—Oximes
    • C07C251/34—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C251/42—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atom of at least one of the oxyimino groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/31—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atoms of the sulfonamide groups bound to acyclic carbon atoms
    • C07C311/32—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atoms of the sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/24—Sulfones; Sulfoxides having sulfone or sulfoxide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/004—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reaction with organometalhalides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/527—Unsaturated compounds containing keto groups bound to rings other than six-membered aromatic rings
    • C07C49/567—Unsaturated compounds containing keto groups bound to rings other than six-membered aromatic rings containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/80—Ketones containing a keto group bound to a six-membered aromatic ring containing halogen
    • C07C49/813—Ketones containing a keto group bound to a six-membered aromatic ring containing halogen polycyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/007—Esters of unsaturated alcohols having the esterified hydroxy group bound to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Definitions

  • the present invention relates to novel heterocyclic aromatic oxazole compounds. More particularly, the present invention relates to heterocyclic aromatic oxazole compounds having antipyretic activity, analgesic activity, anti-inflammatory activity, and in particular, selective inhibitory activity against cyclooxygenase-2 (COX-2), pharmaceutically acceptable salts thereof, intermediates for producing them and pharmaceuticals useful as anti-inflammatory agents causing less side-effects such as disorders in the digestive tract, which comprise these heterocyclic aromatic oxazole compounds.
  • COX-2 cyclooxygenase-2
  • Cyclooxygenase is a synthase which produces prostaglandin H 2 (PGH 2 ) from arachidonic acid via prostaglandin G 2 (PGG 2 ), and includes cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2).
  • the renal blood flow can be increased by promoting the production of vasodilative PGE 2 in the body, thereby to appropriately maintain glomerular filtration rate.
  • the production of such vasodilative PG is suppressed due to the inhibition of COX-1, the renal blood flow becomes less, so that a side-effect such as the onset of ischemic acute renal insufficiency is sometimes caused.
  • COX-2 exists in particular sites such as monocytes, synovial cells, granulosa cells and intravenous endothelial cells, and is topically expressed when inflammation is caused. It is therefore considered that PG generated by COX-2 is deeply concerned with inflammation and tissue disorders.
  • non-steroidal anti-inflammatory drugs such as aspirin, mefenamic acid, diclofenac, indomethacin, ibuprofen and naproxen have been widely used in clinical situations.
  • NSAIDs non-steroidal anti-inflammatory drugs
  • COX cyclooxygenase
  • side-effects are considered to be caused by the fact that they, though certainly selectively inhibit COX, inhibit both COX-1 and COX-2.
  • WO94/15932 discloses, as COX-2 inhibitors, 5-membered heterocyclic compounds substituted by bisaryl, such as thiophene, furan and pyrrole, which are specifically exemplified by 3-(4-methylsulfonylphenyl)-4-(4-fluorophenyl)thiophene.
  • this publication merely shows a 5-membered heterocyclic compound such as thiophene having aryl or heteroary] at the 3-position or 4-position.
  • Japanese Patent Unexamined Publication No. 141261/1991 discloses pyrazole derivatives such as ethyl 1-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]pyrazole-3-carboxylate; Japanese Patent Unexamined Publication No. 183767/1982 discloses thiazole derivatives such as 2-methylthio-5-phenyl-4-(3-pyridyl)-thiazole; and Japanese Patent Unexamined Publication No. 58981/1985 discloses thiazole derivatives such as 2-ethyl-4-(4-methoxyphenyl)-5-(3-pyridyl)-1,3-thiazole.
  • These publications mention that they are useful as anti-inflammatory drugs, whereas they do not disclose if they have selective inhibitory action on COX-2 to reduce side-effects, or any suggestion of it.
  • US Patent No. 4632930 discloses oxazole compounds such as 5-cyclohexyl-4-(4-methylsulfonylphenyl)- ⁇ , ⁇ -bis(trifluoromethyl)oxazole-2-methanol. Yet, the compounds disclosed therein are effective for hypertension and their usefulness as anti-inflammatory drugs or any suggestion to that effect are not included.
  • Japanese Patent Application under PCT laid-open under Kohyo No. 500054/1984 discloses oxazole derivatives having heteroaryl or carbon ring aryl at the 4-position or 5-position of oxazole ring and having carboxy, ester or amidized carboxy via lower alkylene at the 2-position thereof, such as ethyl 2-[4-phenyl-5-(3-pyridyl)-oxazol-2-yl]-propionate; and Japanese Patent Application under PCT laid-open under Kohyo No.
  • imidazole derivatives having heteroaryl and/or carbon ring aryl at the 4-position or 5-position of imidazole ring and having formyl or acetalized formyl via lower alkylene at the 2-position thereof, such as 2-[4-phenyl-5-(3-pyridyl)-imidazol-2-yl]-acetaldehyde dimethyl acetal.
  • These publications teach that these compounds are effective as dermal antiphlogistic or mucosal antiphlogistic for inflammatory dermal diseases, but do not teach or even suggest that they have selective inhibitory action on COX-2.
  • Japanese Patent Unexamined Publication No. 70446/1993 discloses N-thiazolylsulfonamide derivatives such as N-[5-cyclohexyl-4-(4-methoxyphenyl)thiazol-2-y]trifluoromethanesulfonamide; and Japanese Patent Unexamined Publication No. 83372/1990 discloses cyclohexylimidazole derivatives such as 4-cyclohexyl-5-phenyl-2-t-butyl-imidazole.
  • WO94/27980 discloses oxazole compounds such as 2-phenyl-4-cyclohexyl-5-(4-methylsulfonylphenyl)oxazole as COX-2 inhibitors.
  • the compounds described in this publication are mainly characterized by 4-fluorophenyl and 4-methylsulfonylphenyl at the 4-position and 5-position of oxazole ring, and do not suggest the compounds having specific substituents in combination, as in the present invention.
  • phenyl substituent for 5-membered heterocyclic ring skeleton has been conventionally considered to be monosubstituted phenyl such as 4-methylsulfonylphenyl and 4-methoxyphenyl, and di-substituted phenyl has been barely tried (e.g., UK Patent No. 1206403).
  • the present inventors have intensively studied with the aim of providing a novel compound having antipyretic activity, analgesic activity and anti-inflammatory activity, which is free of side-effects such as disorders in the digestive tract.
  • a compound having a secondary substituent such as halogen atom, in particular, fluorine atom, introduced into phenyl such as 4-lower alkylsulfonylphenyl, 4-aminosulfonylphenyl or 4-lower alkylaminosulfonylphenyl, as a substituent for oxazole, has superior selective inhibitory action on COX-2, which resulted in the completion of the present invention.
  • the present invention relates to heterocyclic aromatic oxazole compounds or pharmaceutically acceptable salts thereof, intermediate compounds for producing such compounds and pharmaceutical compositions comprising such heterocyclic aromatic oxazole compound as shown in the following (1) to (22):
  • C 1-4 alkyl means an optionally branched alkyl having 1 to 4 carbon atoms, which is exemplified by methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and tert-butyl, with preference given to methyl.
  • C 1-4 alkylamino means that an amino group is substituted by the above-mentioned C 1-4 alkyl, and is exemplified by methylamino, dimethylamino, ethylamino, diethylamino, propylamino, isopropylamino, butylamino, isobutylamino, sec-butylamino and tert-butylamino. Preferred are methylamino and dimethylamino.
  • Halogen atom means chlorine, bromine and flourine, with preference given to chlorine and fluorine. Particularly preferred is fluorine.
  • C 1-4 alkoxy is an optionally branched alkoxy having 1 to 4 carbon atoms, which is exemplified by methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy and tert-butoxy, with preference given to methoxy.
  • C 5-7 cycloalkyl means a cycloalkyl having 5 to 7 carbon atoms, such as cyclopentyl, cyclohexyl and cycloheptyl. Particularly preferred is cyclohexyl.
  • the 5- or 6-membered heterocyclic group having 1 to 3 hetero atoms selected from nitrogen, oxygen and sulfur is an aromatic heterocyclic ring, a saturated heterocyclic ring or condensed heterocyclic ring of these heterocyclic rings and a benzene ring.
  • Examples thereof include thienyl, furyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, morpholino, piperazinyl, piperidyl, pyranyl, thiopyranyl, pyridyl, benzothienyl, benzofuranyl, indole, 4,5,6,7-tetrahydroindole, 4,5,6,7-tetrahydrobenzothienyl and 4,5,6,7-tetrahydrobenzofuranyl, with preference given to thienyl, furyl, pyrrolyl, morpholino, piperazinyl and piperidyl, and particular preference given to thienyl.
  • aryl residues phenyl, naphthyl and biphenyl is phenyl.
  • Halogenated C 1-4 alkyl is that wherein C 1-4 alkyl is substituted by the above-mentioned halogen atom, and is exemplified by fluoromethyl, chloromethyl, bromomethyl, iodomethyl, difluoromethyl, dichloromethyl, trifluoromethyl, trichloromethyl, fluoroethyl, chloroethyl, difluoroethyl, dichloroethyl, trifluoroethyl, trichloroethyl, tetrachloroethyl, pentafluoroethyl and fluoropropoyl, with preference given to fluoromethyl, chloromethyl, dichloromethyl, difluoromethyl, trichloromethyl and trifluoromethyl.
  • Substituted by 1 to 3 substituents means that said substituents may be the same or different.
  • the position of the substituents is optional and is not particularly limited. Specific examples include C 1-4 alkyl such as methyl, ethyl, propyl, isopropyl, butyl and tert-butyl; hydroxy; C 1-4 alkoxy such as methoxy, ethoxy, propoxy and butoxy; halogen such as fluorine, chlorine and bromine; alkylcarbonyl such as acetyl and propionyl; mercapto; C 1-4 alkylthio such as methylthio, ethylthio, propylthio, butylthio and isobutylthio; alkoxycarbonyl such as methoxycarbonyl, ethoxycarbonyl and propoxycarbonyl; trifluoromethyl; and acylamide such as acetamide and propionylamide.
  • aryl residues phenyl, naphthyl and biphenyl, particularly phenyl may be substituted by halogen, hydroxy, C 1-4 alkyl and C 1-4 alkoxy, and is exemplified by phenyl, fluorophenyl, methylphenyl and methoxy-phenyl, with preference given to phenyl and 4-fluorophenyl.
  • the 5- or 6-membered heterocyclic group may be substituted by halogen, hydroxy, C 1-4 alkyl and C 1-4 alkoxy, and particularly means thienyl, furyl, 5-methylthienyl and 5-chlorothienyl.
  • the C 5-7 cycloalkyl may be substituted by the same substituents set forth above, with preference given to cyclohexyl.
  • R of the heterocyclic aromatic oxazole compounds of the present invention examples include cyclohexyl, 4-fluorophenyl and 5-chlorothienyl, with particular preference given to cyclohexyl.
  • Preferred as R 1 is a group of the formula wherein R 3 , R 4 , R 5 , R 6 and R 7 are as defined above, with particular preference given to a group wherein R 3 is amino or methyl, R 4 and R 7 are hydrogen atoms and at least one of R 5 and R 6 is fluorine atom.
  • R 2 is methyl
  • Pharmaceutically acceptable salt may be any as long as it forms a non-toxic salt with the oxazole derivative of the formula (I).
  • Alkali metal salts such as sodium salt and potassium salt, alkaline earth metal salts such as magnesium salt and calcium salt, ammonium salt, organic base salts such as trimethylamine salt, triethylamine salt, pyridine salt, picoline salt, dicyclohexylamine salt and N,N'-dibenzylethylenediamine salt, and amino acid salts such as lysine salt and arginine salt are among the examples. It may be a hydrate as the case demands.
  • the compound of the present invention has particularly superior selective inhibitory action on COX-2 and is expected to make a therapeutic drug useful for antipyresis, pain relief and anti-inflammation, which is free of side-effects such as digestive tract disorders.
  • the compound of the formula (I) of the present invention or a pharmaceutically acceptable salt thereof is used as a pharmaceutical preparation, it is generally admixed with pharmacologically acceptable carriers, excipients, diluents, extenders, disintegrators, stabilizers, preservatives, buffers, emulsifying agents, aromatics, colorings, sweeteners, thickeners, flavorings, solubilizers and other additives known per se , such as water, vegetable oil, alcohol such as ethanol and benzyl alcohol, polyethylene glycol, glycerol triacetate gelatin, carbohydrates such as lactose and starch, magnesium stearate, talc, lanolin and petrolatum, and formulated into, by a conventional method, tablets, pills, powders, granules, suppositories, injections, eye drops, liquids, capsules, troches, aerosols, elixirs, suspensions, emulsions and syrups, which can be administered orally
  • R 2 ' is C 1-4 alkyl or halogenated C 1-4 alkyl wherein R 2 ' may be the same with or different from R 2 , X and X' are the same or different and each is halogen such as bromine and chlorine,
  • X 1 is halogen or hydroxy
  • X 1 ' is halogen or hydroxy or an alkali metal derivative thereof
  • R, R 1 and R 2 are as defined above.
  • Compound (IV) can be synthesized by reacting compound (II) with compound (III) in the presence of a metal such as zinc and magnesium in an inert solvent such as 1,2-dimethoxyethane, dioxane, ether, tetrahydrofuran, methylene chloride, benzene and toluene at room temperature.
  • a catalyst such as palladium(O) complex and copper(I) complex may be added.
  • Compound (V) can be synthesized by reacting compound (IV) in acetic acid solvent in the presence of lead tetraacetate, or by refluxing compound (IV) under heating in the presence of a complex such as manganese acetate, in lower alkanecarboxylic acid such as acetic acid and propionic acid corresponding to R 2 COOH wherein R 2 is as defined above and benzoic acid and a solvent such as benzene as necessary.
  • Compound (I) can be synthesized by refluxing compound (V) under heating in the presence of ammonium salt (e.g., lower alkanecarboxylic acid ammonium such as ammonium acetate and ammonium formate), and inorganic ammonium such as ammonium carbonate in an acidic solvent such as lower alkanecarboxylic acid (e.g., formic acid, acetic acid and propionic acid).
  • ammonium salt e.g., lower alkanecarboxylic acid ammonium such as ammonium acetate and ammonium formate
  • inorganic ammonium such as ammonium carbonate
  • an acidic solvent such as lower alkanecarboxylic acid
  • R or R 1 is aromatic heterocycle, isomers may be produced wherein the 4-position R and the 5-position R 1 are reversed.
  • Compound (I) can be also synthesized by the following route.
  • Step 4 wherein X 1 is hydroxy
  • Step 6 and Step 7 are advantageous when R 2 (e.g., methyl) is converted to other R 2 (e.g., R 2 ' such as ethyl).
  • R 2 e.g., methyl
  • R 2 ' such as ethyl
  • compound (VI) can be synthesized by reacting compound (V) in the presence of a base such as potassium carbonate, lithium hydroxide, sodium hydroxide and potassium hydroxide in an organic solvent such as methanol, ethanol and dioxane, water or a mixed solvent thereof from under cooling to under heating.
  • a base such as potassium carbonate, lithium hydroxide, sodium hydroxide and potassium hydroxide
  • organic solvent such as methanol, ethanol and dioxane, water or a mixed solvent thereof from under cooling to under heating.
  • Compound (VI) can be also synthesized by the following Step 5.
  • Step 5 wherein X 1 is halogen or hydroxy
  • Compound (VI) can be synthesized by reacting compound (IV) in the presence of a halogenating agent such as bromine, chlorine and N-bromosuccinimide in an inert solvent such as acetic acid, 1,2-dimethoxyethane, dioxane, ether, tetrahydrofuran, methylene chloride, benzene and toluene to give compound (VI) wherein X 1 is halogen.
  • a halogenating agent such as bromine, chlorine and N-bromosuccinimide
  • an inert solvent such as acetic acid, 1,2-dimethoxyethane, dioxane, ether, tetrahydrofuran, methylene chloride, benzene and toluene
  • Compound (VI) wherein X 1 is hydroxy can be synthesized by oxidizing compound (IV) with an oxidizing agent such as benzene iodoacetate, or by treating the halogenated compound (VI) obtained above with water in an inert solvent such as acetone, 1,2-dimethoxyethane, dioxane, ether, tetrahydrofuran, benzene and toluene.
  • an oxidizing agent such as benzene iodoacetate
  • Compound (V') can be obtained by reacting compound (VI) and compound (VII') by a known method. Specifically, compound (VI) wherein X 1 is hydroxy and compound (VII') wherein X 1 ' is halogen, or compound (VI) wherein X 1 is halogen and compound (VII') wherein X 1 ' is hydroxy are reacted in pyridine, or in the presence of a base such as triethylamine and sodium hydroxide, in an organic solvent such as methylene chloride, chloroform and ethanol, from under cooling to under heating.
  • a base such as sodium acetate may be used instead of carboxylic acid compound (VII'). In this case, a base may or may not be added.
  • Compound (I') can be obtained by treating compound (V') in the same manner as in Step 3.
  • the compound When a compound wherein either R or R 1 is 4-aminosulfonyl-3-fluorophenyl is desired, the compound can be produced from a compound having 3-fluoro-4-methylsulfonylphenyl corresponding to the objective compound by a known method.
  • compound (IV) instead of obtaining compound (IV) using, as mentioned above, compound (II) or (III) having, as R or R 1 , wherein R 3 , R 4 , R 5 , R 6 and R 7 are as defined above, compound (II') or (III') having wherein R 4 , R 5 , R 6 and R 7 are as defined above, may be used as a starting material to give compound (IV') according to Step 10, which compound is then converted to aminosulfonyl or methylsulfonyl according to the method of Step 15 to give compound (IV).
  • such starting materials (II') and (III') may be used to give a non-sulfonylated oxazole compound (XIII) corresponding to the ultimate compound (I) or (I') according to Step 1 to Step 7, and the obtained compound (XIII) may be subjected to sulfonylation in the same manner as in Step 15 to give the objective compound (I) or (I').
  • compound (X) wherein either R 8 or R 9 is methoxysulfonylphenyl is subjected to the following Step 8 and Step 9 to synthesize compound (IV).
  • R 8 or R 9 is methoxysulfonylphenyl of the formula wherein R 4 , R 5 , R 6 and R 7 are as defined above, and the other is an optionally substituted phenyl, naphthyl, biphenyl, C 5-7 cycloalkyl, or 5- or 6- membered heterocylic group as defined above, and R, R 1 , X and X' are as defined above.
  • Compound (X) can be synthesized in the same manner as in Step 1, using compound (VIII) and compound (IX).
  • compound (IV) can be synthesized by heating compound (X) in pyridine, or refluxing compound (X) under heating in the presence of sodium iodide, potassium iodide or lithium iodide in an organic solvent such as acetone and tetrahydrofuran, after which the obtained compound is reacted with thionyl chloride or oxalyl chloride under heating. Then, the resulting product is aminated or alkylaminated or alkylated by a known method.
  • amination or alkylamination is carried out by reacting the resulting product in the presence of aqueous ammonia or alkylamine, or a base such as sodium acetate and ammonium salt such as alkylamine hydrochloride, in an organic solvent such as tetrahydnofuran, ether, toluene, benzene, methylene chloride and dioxane from under cooling to under heating.
  • the alkylation can be carried out by the method described in J. Org. Chem., 56: 4974-4976 (1991).
  • Compound (I) can be also synthesized by the method of the following Step 10 to Step 15.
  • R' or R 1 ' is phenyl of the formula wherein R 4 , R 5 , R 6 and R 7 are as defined above, and the other is a group corresponding to one of R and R 1 , C 5-7 cycloalkyl which may be substituted by a substituent such as C 1-4 alkyl, a 5- or 6-membered heterocyclic group such as thienyl and furyl, which may be substituted by a C 1-4 alkyl or halogen, or a phenyl, napththyl or biphenyl group which may be substituted by a substituent such as halogen, C 1-4 alkyl or C 1-4 alkoxy, and R, R 1 , X, and X' are as defined above.
  • Compound (IV') can be synthesized in the same manner as in Step 1, wherein compound (II') and compound (III') are reacted in the presence of a metal such as zinc and magnesium in an inert solvent such as 1,2-dimethoxyethane, dioxane, ether, tetrahydrofuran, methylene chloride, benzene and toluene at room temperature.
  • a metal such as zinc and magnesium
  • an inert solvent such as 1,2-dimethoxyethane, dioxane, ether, tetrahydrofuran, methylene chloride, benzene and toluene at room temperature.
  • a catalyst such as palladium(O) complex and copper(I) iodide complex may be added.
  • Compound (XI) can be synthesized by refluxing under heating compound (IV') and hydroxylammine hydrochloride in the presence of a base such as sodium acetate, sodium hydroxide and potassium carbonate in an organic solvent such as methanol, ethanol and tetrahydrofuran, water or a mixed solvent thereof.
  • a base such as sodium acetate, sodium hydroxide and potassium carbonate
  • an organic solvent such as methanol, ethanol and tetrahydrofuran, water or a mixed solvent thereof.
  • Compound (XII) can be synthesized by reacting compound (XI) in the presence of an acylating agent such as acetic anhydride and acetyl chloride, in pyridine, or in the presence of a base such as triethylamine in an organic solvent such as methylene chloride and chloroform from under cooling to under heating.
  • an acylating agent such as acetic anhydride and acetyl chloride
  • a base such as triethylamine
  • organic solvent such as methylene chloride and chloroform
  • Compound (XIII) can be synthesized by refluxing under heating compound (XII) in an acidic solvent such as formic acid and acetic acid.
  • a dehydrating agent such as magnesium sulfate and sodium sulfate may be added.
  • This step is for the synthesis of compound (XIII) from compound (XI) in a single step, and compound (XIII) can be synthesized from compound (XI) and carboxylic acid chloride such as acetyl chloride by the method described in Indian J. Chem., 20B: 322-323 (1981).
  • compound (XIII) can be synthesized by reacting compound (XI) and acetic anhydride while heating in acetic acid.
  • Compound (I) can be synthesized by reacting compound (XIII) in the presence of a chlorosulfonylating agent such as chlorosulfonic acid in an organic solvent such as chloroform and methylene chloride, or without solvent, and subjecting the resulting product to amination, alkylamination or alkylation by a known method.
  • a chlorosulfonylating agent such as chlorosulfonic acid
  • organic solvent such as chloroform and methylene chloride
  • the amination and alkylamination in Step 15 specifically comprise reacting in the presence of aqueous ammonia, alkylamine or a base such as sodium acetate and ammonium salt such as alkylamine hydrochloride in an organic solvent such as tetrahydrofuran, ether, toluene, benzene, methylene chloride and dioxane from under cooling to under heating.
  • aqueous ammonia, alkylamine or a base such as sodium acetate and ammonium salt
  • alkylamine hydrochloride in an organic solvent such as tetrahydrofuran, ether, toluene, benzene, methylene chloride and dioxane from under cooling to under heating.
  • Compound (XIII) used in Step 15 can be also synthesized by the following route. wherein R 1 , R 1 ' and R 2 are as defined above.
  • Compound (V'') can be synthesized in the same manner as in Step 2 wherein compound (IV') is reacted in the presence of lead tetraacetate in acetic acid solvent, or by heating compound (IV') in the presence of a complex such as manganese acetate in lower alkanecarboxylic acid such as acetic acid and propionic acid corresponding to R 2 COOH wherein R 2 is as defined above, and benzoic acid and in a solvent such as benzene as necessary.
  • a complex such as manganese acetate in lower alkanecarboxylic acid such as acetic acid and propionic acid corresponding to R 2 COOH wherein R 2 is as defined above, and benzoic acid and in a solvent such as benzene as necessary.
  • Compound (XIII) can be synthesized in the same manner as in Step 3 wherein compound (V'') is refluxed under heating in the presence of ammonium salt such as lower alkanecarboxylic acid ammonium (e.g., ammonium acetate and ammonium formate) and inorganic ammonium (e.g., ammonium carbonate) in an acidic solvent of lower alkanecarboxylic acid such as formic acid, acetic acid and propionic acid.
  • ammonium salt such as lower alkanecarboxylic acid ammonium (e.g., ammonium acetate and ammonium formate) and inorganic ammonium (e.g., ammonium carbonate) in an acidic solvent of lower alkanecarboxylic acid such as formic acid, acetic acid and propionic acid.
  • ammonium salt such as lower alkanecarboxylic acid ammonium (e.g., ammonium acetate and ammonium formate) and in
  • Compound (I) can be also synthesized by the method shown in the following Step 18 to Step 21. wherein X 2 is halogen atom, and R, R 1 , R', R 1 ' and R 2 are as defined above.
  • Compound (XV) can be synthesized by reacting compound (XIV) with chlorocarbonate such as ethyl chlorocaronate in an inert solvent such as tetrahydrofuran, toluene and ethyl acetate in the presence of a base such as triethylamine, or by heating compound (XIV) in acetic anhydride.
  • chlorocarbonate such as ethyl chlorocaronate
  • an inert solvent such as tetrahydrofuran, toluene and ethyl acetate
  • a base such as triethylamine
  • Compound (XVII) can be synthesized by reacting compound (XV) with compound (XVI) or an acid anhydride corresponding to compound (XVI) in an inert solvent such as tetrahydrofuran, acetonitrile, ethyl acetate and toluene in the presence of magnesium salt such as magnesium chloride and a base such as triethylamine, pyridine and potassium carbonate.
  • Compound (XVII) can be also synthesized by the method described in Chem. Ber., 102: 883-898 (1969).
  • Compound (XVIII) can be synthesized by treating compound (XVII) with an acid such as 1N-4N hydrochloric acid, oxalic solid and dilute sulfuric acid in an inert solvent such as tetrahydrofuran, dioxane, methylene chloride and toluene, or heating compound (XVII) in the presence of pyridine and acetic acid.
  • an acid such as 1N-4N hydrochloric acid, oxalic solid and dilute sulfuric acid in an inert solvent such as tetrahydrofuran, dioxane, methylene chloride and toluene, or heating compound (XVII) in the presence of pyridine and acetic acid.
  • Compound (I) is obtained by reacting compound (XVIII) with a chlorosulfonylating agent such as chlorosulfonic acid in an organic solvent such as chloroform and methylene chloride, or without solvent. Then, the obtained product is reacted with aqueous ammonia or alkylamine in an orgnic solvent such as tetrahydrofuran, ether, toluene, methylene chloride and dioxane, or reacted with ammonium salt such as alkylamine hydrochloride in the presence of a base such as sodium acetate, pyridine and sodium hydroxide.
  • a chlorosulfonylating agent such as chlorosulfonic acid
  • organic solvent such as chloroform and methylene chloride, or without solvent.
  • Compound (I) can be also synthesized from compound (XVIII) by the following Step 22 and Step 23.
  • Compound (XIII) can be synthesized by reacting compound (XVIII) with inorganic acid such as concentrated sulfuric acid and polyphosphoric acid in acetic anhydride, or without solvent, at room temperature to under heating.
  • inorganic acid such as concentrated sulfuric acid and polyphosphoric acid in acetic anhydride, or without solvent
  • Compound (I) can be synthesized by reacting compound (XIII) in the same manner as in the aforementioned Step 15.
  • Step 22 and Step 23 alkylsulfonylation or aminosulfonylation in the final Step 23 has been exemplarily discussed. It is possible to subject a compound having R and R 1 instead of R' and R 1 ' to the reaction according to Step 18 to Step 20, followed by Step 22 to give an oxazole compound (I). In this case, Step 23 is not necessary.
  • the compound (I) thus obtained can be isolated and purified by a known method for separation and purification, such as concentration, concentration under reduced pressure, solvent extraction, crystal precipitation, recrystallization and chromatography.
  • Aqueous ammonia (28%) was added to a solution of the obtained compound (10.00 g) in tetrahydrofuran (40 ml) with stirring at room temperature, and the mixture was stirred at room temperature for one hour.
  • the solvent was evaporated under reduced pressure and ethyl acetate was added to the residue.
  • the mixture was washed with water and saturated brine, and dried over anhydrous sodium sulfate.
  • Acetic anhydride (95 ml) was dropwise added to a solution of the compound (158 g) obtained in the above Step 11) in acetic acid (900 ml) with stirring at room temperature, and the mixture was refluxed under heating for 7 hours. The solvent was evaporated under reduced pressure and n-heptane was added to the residue. The mixture was washed with water, saturated aqueous sodium hydrogencarbonate solution, saturated brine and acetonitrile. The solvent was evaporated under reduced pressure to give 119 g of the title compound as an oil.
  • Triethylamine (8.39 ml) was added to a suspension of DL-N-acetyl2-cyclohexylglycine (10.00 g) obtained from ⁇ -aminophenylacetic acid according to a known method [Collect. Czeck. Chem. Commun., 31: 4563 (1996)] in ethyl acetate (50 ml).
  • Ethyl chlorocarbonate (5.28 ml) was dropwise added to the mixture under ice-cooling. The mixture was stirred under ice-cooling for one hour, added with ethyl acetate (150 ml), and washed successively with water and saturated brine. The ethyl acetate solution was concentrated under reduced pressure to give 9.86 g of the title compound as an oil.
  • the enzymatic activity was determined from the percent conversion of 1 4 C arachidonic acid into prostaglandin H 2 (PGH 2 ) and the decomposed product thereof. That is, a test sample (20 ⁇ l), an enzyme solution (20 ⁇ l) and distilled water (10 ⁇ l) were added to 100 mM Tris-HCl buffer (pH 8, 140 ⁇ l) containing hematin (2 ⁇ M) and tryptophan (5 mM), and the mixture was thoroughly stirred, which was followed by preincubation at 24°C for 5 minutes.
  • control compound 1 was 5-(4-aminosulfonylphenyl)-4-cyclohexyl-2-methyloxazole, disclosed in EP-A-0 826 676, and control compound 2 was a known analogous compound, 5-(4-aminosulfonylphenyl)-4-(4-fluorophenyl)-2-methyloxazole.
  • Carrageenin (1%, 0.05 ml) dissolved in physiological saline was subcutaneously injected to the left hindlimb of male Donryu rats to induce podedema.
  • the degree of podedema was evaluated by measuring the volume of the limb 3 hours after carrageenin administration.
  • a test compound (1, 3, 10 or 30 mg/kg) was orally administered one hour before carrageenin administration, and suppression thereby was studied.
  • Inhibitory activity was expressed by the dose (ED 30 ) of the test compound necessary for inhibiting by 30% relative to the control group. The results are shown in Table 5.
  • Experimental Example 2 effects on carrageenin-induced podedema in rats
  • the compound of the present invention in particular, a compound wherein R 3 is methyl or amino, R 5 is fluorine atom, R 6 is hydrogen atom or fluorine atom, and R 4 and R 7 are hydrogen atom, and pharmaceutically acceptable salts thereof surprisingly selectively inhibit COX-2 alone, while scarcely inhibiting COX-1. Accordingly, the compound of the present invention possesses superior antipyretic action, analgesic action and anti-inflammatory action that the conventional products cannot afford, and scarcely show side-effects in the digestive tract.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Claims (22)

  1. Heterocyclische aromatische Oxazolverbindung der Formel (I)
    Figure 00480001
    wobei
    einer der Reste R und R1 eine Gruppe der Formel
    Figure 00480002
    ist, wobei R3 C1-4-Alkyl, Amino oder C1-4-Alkylamino ist und R4, R5, R6 und R7 gleich oder verschieden sind und jeweils Wasserstoff oder Fluor sind, mit der Maßgabe, daß wenigstens einer der Reste R4, R5, R6 und R7 nicht Wasserstoff ist;
    und der andere Rest, d.h. R1 oder R, eine Gruppe ist, die aus Phenyl, Naphthyl, Biphenyl, C5-7-Cycloalkyl und einer fünf- oder sechsgliedrigen heterocyclischen Gruppe mit 1 bis 3 Heteroatomen, die aus Stickstoff, Sauerstoff und Schwefel ausgewählt sind, ausgewählt ist, wobei die Gruppen unsubstituiert oder mit 1 bis 3 Substituenten substituiert sind, die aus Hydroxy, C1-4-Alkyl, C1-4-Alkoxy, Mercapto, C1-4-Alkylthio, Halogen, Trifluormethyl, Alkylcarbonyl, Alkoxycarbonyl und Acylamid ausgewählt sind; und
    R2 C1-4-Alkyl oder halogeniertes C1-4-Alkyl ist;
    oder ein pharmazeutisch annehmbares Salz davon.
  2. Heterocyclische aromatische Oxazolverbindung gemäß Anspruch 1, wobei R1 eine Gruppe der Formel
    Figure 00490001
    ist, wobei R3'' Methyl oder Amino ist, R5'' Fluor ist und R6'' Wasserstoff oder Fluor ist; und
    R2 Methyl ist;
    oder ein pharmazeutisch annehmbares Salz davon.
  3. Heterocyclische aromatische Oxazolverbindung gemäß Anspruch 1, wobei R1 eine Gruppe der Formel
    Figure 00490002
    ist, wobei R3'', R5'' und R6'' wie in Anspruch 2 definiert sind;
    R eine Gruppe ist, die aus C5-7-Cycloalkyl, Thienyl, Furyl, Pyrrolyl, Morpholino, Piperazinyl, Piperidyl, Phenyl, Naphthyl und Biphenyl ausgewählt ist, wobei die Gruppen unsubstituiert oder mit 1 bis 3 Substituenten, wie sie in Anspruch 1 definiert sind, substituiert sind; und
    R2 Methyl ist;
    oder ein pharmazeutisch annehmbares Salz davon.
  4. Heterocyclische aromatische Oxazolverbindung gemäß Anspruch 3, wobei R3'' Amino ist, oder ein pharmazeutisch annehmbares Salz davon.
  5. Heterocyclische aromatische Oxazolverbindung gemäß Anspruch 3, wobei R eine Gruppe ist, die aus C5-7-Cycloalkyl, Phenyl und Thienyl ausgewählt ist, wobei die Gruppen unsubstituiert oder mit 1 bis 3 Substituenten, wie sie in Anspruch 1 definiert sind, substituiert sind, oder ein pharmazeutisch annehmbares Salz davon.
  6. Heterocyclische aromatische Oxazolverbindung gemäß Anspruch 3, wobei R Cyclohexyl oder 4-Fluorphenyl ist und R1 4-Aminosulfonyl-3-fluorphenyl, 4-Aminosulfonyl-3,5-difluorphenyl, 3-Fluor-4-methylsulfonylphenyl oder 3,5-Difluor-4-methylsulfonylphenyl ist, oder ein pharmazeutisch annehmbares Salz davon.
  7. Heterocyclische aromatische Oxazolverbindung gemäß Anspruch 1, die aus 4-Cyclohexyl-5-(3-fluor-4-methylsulfonylphenyl)-2-methyloxazol, 5-(4-Aminosulfonyl-3-fluorphenyl)-4-cyclohexyl-2-methyloxazol, 5-(4-Aminosulfonyl-3,5-difluorphenyl)-4-cyclohexyl-2-methyloxazol, 4-Cyclohexyl-5-(3,5-difluor-4-methylsulfonylphenyl)-2-methyloxazol und 5-(4-Aminosulfonyl-3-fluorphenyl)-4-(4-fluorphenyl)-2-methyloxazol ausgewählt ist, oder ein pharmazeutisch annehmbares Salz davon.
  8. Oximverbindung der folgenden Formel (XI')
    Figure 00510001
    wobei R1''
    Figure 00510002
    ist, wobei R4, R5, R6 und R7 wie in Anspruch 1 definiert sind, und R'' Cyclohexyl oder 4-Fluorphenyl ist.
  9. Oximverbindung gemäß Anspruch 8, wobei R1'' 3-Fluorphenyl oder 3,5-Difluorphenyl ist.
  10. Ketonverbindung der folgenden Formel (IV'')
    Figure 00510003
    wobei R1''
    Figure 00520001
    ist, wobei R4, R5, R6 und R7 wie in Anspruch 1 definiert sind, und R'' Cyclohexyl oder 4-Fluorphenyl ist.
  11. Ketonverbindung gemäß Anspruch 10, wobei R1'' 3-Fluorphenyl oder 3,5-Difluorphenyl ist.
  12. Ketomethylenverbindung der folgenden Formel
    Figure 00520002
    wobei R''' eine Gruppe ist, die aus C5-7-Cycloalkyl, Phenyl und Thienyl ausgewählt ist, wobei die Gruppen unsubstituiert oder mit 1 bis 3 Substituenten, wie sie in Anspruch 1 definiert sind, substituiert sind, und R1''' eine Gruppe der Formel
    Figure 00520003
    ist, wobei R3, R4, R5, R6 und R7 wie in Anspruch 1 definiert sind.
  13. Ketomethylenverbindung gemäß Anspruch 12, wobei R''' Cyclohexyl ist und R1''' 4-Aminosulfonyl-3-fluorphenyl, 4-Aminosulfonyl-3,5-difluorphenyl, 3-Fluor-4-methylsulfonylphenyl oder 3,5-Difluor-4-methylsulfonylphenyl ist.
  14. Esterverbindung der folgenden Formel (V)
    Figure 00530001
    Wobei R, R1 und R2 wie in Anspruch 1 definiert sind.
  15. Esterverbindung gemäß Anspruch 14, wobei R C5-7-Cycloalkyl ist und R2 C1-4-Alkyl ist.
  16. Amidverbindung der folgenden Formel (XVIII''')
    Figure 00530002
    wobei einer der Reste R' und R1' eine Gruppe der Formel
    Figure 00530003
    Figure 00540001
    ist, wobei R3, R4, R5, R6 und R7 wie in Anspruch 1 definiert sind, und der andere Cyclohexyl oder 4-Fluorphenyl ist; und
    R2 C1-4-Alkyl oder halogeniertes C1-4-Alkyl ist.
  17. Amidverbindung gemäß Anspruch 1, wobei R1'
    Figure 00540002
    ist, wobei R4, R5, R6 und R7 wie in Anspruch 1 definiert sind, und R' Cyclohexyl oder 4-Fluorphenyl ist.
  18. Amidverbindung gemäß Anspruch 17, wobei R1'3-Fluorphenyl oder 3,5-Difluorphenyl ist und R2 C1-4-Alkyl ist.
  19. Verbindung der Formel (XVII')
    Figure 00540003
    wobei einer der Reste R und R1 eine Gruppe der Formel
    Figure 00550001
    ist, wobei R3, R4, R5, R6 und R7 wie in Anspruch 1 definiert sind, und der andere Cyclohexyl oder 4-Fluorphenyl ist; und
    R2 C1-4-Alkyl oder halogeniertes C1-4-Alkyl ist.
  20. Pharmazeutische Zusammensetzung, die einen pharmazeutisch annehmbaren Träger sowie eine heterocyclische aromatische Oxazolverbindung gemäß Anspruch 1 oder ein pharmazeutisch annehmbares Salz davon umfaßt.
  21. Cyclooxygenase-2-Inhibitor, der einen pharmazeutisch annehmbaren Träger sowie eine heterocyclische aromatische Oxazolverbindung gemäß Anspruch 1 oder ein pharmazeutisch annehmbares Salz davon als Wirkstoff umfaßt.
  22. Entzündungshemmendes Mittel, das einen pharmazeutisch annehmbaren Träger sowie eine heterocyclische aromatische Oxazolverbindung gemäß Anspruch 1 oder ein pharmazeutisch annehmbares Salz davon als Wirkstoff umfaßt.
EP95940466A 1994-12-20 1995-12-18 Hetero aromatische oxazole und deren verwendung Expired - Lifetime EP0745596B1 (de)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
JP33583894 1994-12-20
JP335838/94 1994-12-20
JP93099/95 1995-03-27
JP9309995 1995-03-27
JP16465695 1995-06-06
JP164656/95 1995-06-06
JP326571/95 1995-11-20
JP7326571A JP2636819B2 (ja) 1994-12-20 1995-11-20 オキサゾール系複素環式芳香族化合物
PCT/JP1995/002600 WO1996019463A1 (fr) 1994-12-20 1995-12-18 Composes heteroatomiques d'oxazole et leur emploi

Publications (3)

Publication Number Publication Date
EP0745596A1 EP0745596A1 (de) 1996-12-04
EP0745596A4 EP0745596A4 (de) 1997-05-02
EP0745596B1 true EP0745596B1 (de) 1999-05-19

Family

ID=27468109

Family Applications (1)

Application Number Title Priority Date Filing Date
EP95940466A Expired - Lifetime EP0745596B1 (de) 1994-12-20 1995-12-18 Hetero aromatische oxazole und deren verwendung

Country Status (22)

Country Link
US (8) US5994381A (de)
EP (1) EP0745596B1 (de)
JP (1) JP2636819B2 (de)
KR (1) KR100201581B1 (de)
CN (1) CN1146204A (de)
AT (1) ATE180253T1 (de)
AU (1) AU695045B2 (de)
BR (1) BR9506815A (de)
CA (2) CA2183645A1 (de)
CZ (1) CZ285476B6 (de)
DE (1) DE69509753T2 (de)
DK (1) DK0745596T3 (de)
ES (1) ES2132751T3 (de)
FI (1) FI963238A (de)
GR (1) GR3030643T3 (de)
HU (1) HUT76541A (de)
MX (1) MX9603506A (de)
NO (1) NO306778B1 (de)
NZ (1) NZ297105A (de)
SK (1) SK281468B6 (de)
TW (1) TW403742B (de)
WO (1) WO1996019463A1 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8247423B2 (en) 2007-07-12 2012-08-21 Tragara Pharmaceuticals, Inc. Methods and compositions for the treatment of cancer, tumors, and tumor-related disorders

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2636819B2 (ja) * 1994-12-20 1997-07-30 日本たばこ産業株式会社 オキサゾール系複素環式芳香族化合物
WO1996036617A1 (en) 1995-05-19 1996-11-21 G.D. Searle & Co. Substituted oxazoles for the treatment of inflammation
ES2125161B1 (es) 1996-03-21 1999-11-16 Grupo Farmaceutico Almirall S Nuevos derivados de 2-(3h)-oxazolona.
US5908858A (en) * 1996-04-05 1999-06-01 Sankyo Company, Limited 1,2-diphenylpyrrole derivatives, their preparation and their therapeutic uses
TR199802049T2 (xx) * 1996-04-12 1999-01-18 G.D.Searle & Co. COX-2 Inhibit�rlerinin �nilac� olarak s�bstit�e edilmi� benzens�lfonamid t�revleri.
ATE231504T1 (de) * 1997-04-11 2003-02-15 Grelan Pharmaceutical Co Pyrazolderivate und sie enthaltende cox- inhibitoren
US20040072889A1 (en) * 1997-04-21 2004-04-15 Pharmacia Corporation Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia
WO1998051667A1 (fr) * 1997-05-16 1998-11-19 Chugai Seiyaku Kabushiki Kaisha Derives d'indole et derives de mono- et diazaindole
US6255304B1 (en) * 1997-05-30 2001-07-03 Pharmacia & Upjohn Company Oxazolidinone antibacterial agents having a thiocarbonyl functionality
NZ333399A (en) * 1997-12-24 2000-05-26 Sankyo Co Cyclooxygenase-2 inhibitors (COX-2) for the prevention and treatment of tumors, cachexia and tumor-metastasis
US6294558B1 (en) 1999-05-31 2001-09-25 Pfizer Inc. Sulfonylbenzene compounds as anti-inflammatory/analgesic agents
US6727238B2 (en) * 1998-06-11 2004-04-27 Pfizer Inc. Sulfonylbenzene compounds as anti-inflammatory/analgesic agents
TW477789B (en) 1998-09-03 2002-03-01 Japan Tobacco Inc Production method of oxazole compound
DE69922688T2 (de) * 1998-11-02 2005-12-01 Merck & Co. Inc. Zusammensetzungen aus einem 5ht1b/1d agonisten und einem selektiven cox-2 hemmer zur behandlung von migräne
US20040122011A1 (en) * 1998-12-23 2004-06-24 Pharmacia Corporation Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy
EP1156855A1 (de) * 1999-03-01 2001-11-28 Ortho-McNeil Pharmaceutical, Inc. Zusammensetzung mit einem tramadol-material und einem selektiven cox-2 inhibitor
WO2001045703A1 (en) * 1999-12-23 2001-06-28 Nitromed, Inc. Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use
JP2003531202A (ja) * 2000-04-25 2003-10-21 ファルマシア・コーポレーション ３，４−ジ（カルボシクリルまたはヘテロシクリル）チオフェンの位置選択的合成
AU2001268103A1 (en) * 2000-05-26 2001-12-11 Ortho-Mcneil Pharmaceutical, Inc. Amorphous oxazole coumpound and its use as cox-2 inhibitor
JP2002179657A (ja) * 2000-05-26 2002-06-26 Japan Tobacco Inc ５−（４−アミノスルホニル−３−フルオロフェニル）−４−シクロヘキシル−２−メチルオキサゾールの結晶多形
CA2414674A1 (en) * 2000-07-13 2002-01-24 Pharmacia Corporation Use of cox-2 inhibitors in the treatment and prevention of ocular cox-2 mediated disorders
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
JP2004522754A (ja) * 2001-02-02 2004-07-29 ファルマシア・コーポレーション 月経困難症の治療および予防のための組み合わせ治療としてシクロオキシゲナーゼ‐２阻害剤および性ステロイドを使用する方法
US7695736B2 (en) 2001-04-03 2010-04-13 Pfizer Inc. Reconstitutable parenteral composition
US6673818B2 (en) 2001-04-20 2004-01-06 Pharmacia Corporation Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation
US20060167074A1 (en) * 2001-06-19 2006-07-27 Norbert Muller Methods and compositions for the treatment of psychiatric disorders
DE10129320A1 (de) * 2001-06-19 2003-04-10 Norbert Mueller Verwendung von COX-2 Inhibitoren zur Behandlung von Schizophrenie, wahnhaften Störungen, affektiven Störungen oder Ticstörungen
UA80682C2 (en) * 2001-08-06 2007-10-25 Pharmacia Corp Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition
AR038957A1 (es) 2001-08-15 2005-02-02 Pharmacia Corp Terapia de combinacion para el tratamiento del cancer
US20040062823A1 (en) * 2001-12-13 2004-04-01 Obukowicz Mark G. Selective cox-2 inhibition from non-edible plant extracts
US20030212138A1 (en) * 2002-01-14 2003-11-13 Pharmacia Corporation Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor
US20030220374A1 (en) * 2002-01-14 2003-11-27 Pharmacia Corporation Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
ITMI20021391A1 (it) * 2002-06-25 2003-12-29 Nicox Sa Nitroderivati di inibitori della cicloossigenasi-2
CA2489428A1 (en) * 2002-06-27 2004-01-08 Nitromed, Inc. Cyclooxygenase-2 selective inhibitors, compositions and methods of use
US7211598B2 (en) * 2002-06-28 2007-05-01 Nitromed, Inc. Oxime and/or hydrozone containing nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use
US20040147581A1 (en) * 2002-11-18 2004-07-29 Pharmacia Corporation Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
KR20090118994A (ko) 2002-12-13 2009-11-18 워너-램버트 캄파니 엘엘씨 하부요로증상을 치료하기 위한 알파-2-델타 리간드
ES2215474B1 (es) 2002-12-24 2005-12-16 J. URIACH & CIA S.A. Nuevos derivados de fosforamida.
TW200505446A (en) * 2003-01-17 2005-02-16 Fuj Isawa Pharmaceutical Co Ltd Inhibitor of cox
US20040220155A1 (en) * 2003-03-28 2004-11-04 Pharmacia Corporation Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith
ES2275218T3 (es) 2003-05-07 2007-06-01 Osteologix A/S Sales de estroncio hidrosolubles para el tratamiento de afecciones de cartilagos y/o huesos.
DK1622630T3 (da) 2003-05-07 2012-12-17 Osteologix As P009368epdk1
WO2005009342A2 (en) * 2003-07-16 2005-02-03 Pharmacia Corporation Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith
US20050119262A1 (en) * 2003-08-21 2005-06-02 Pharmacia Corporation Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent
US20050107350A1 (en) * 2003-08-22 2005-05-19 Pharmacia Corporation Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith
US20050187278A1 (en) * 2003-08-28 2005-08-25 Pharmacia Corporation Treatment or prevention of vascular disorders with Cox-2 inhibitors in combination with cyclic AMP-specific phosphodiesterase inhibitors
WO2005023189A2 (en) * 2003-09-03 2005-03-17 Pharmacia Corporation Method of cox-2 selective inhibitor and nitric oxide-donating agent
EP1708718A1 (de) 2004-01-22 2006-10-11 Pfizer Limited Triazol-derivate zur hemmung der vasopressing-antagonistischen aktivität
BRPI0510340A (pt) * 2004-04-28 2007-10-30 Pfizer derivados de 3-heterociclil-4-feniltriazol como inibidores do receptor via da vasopressina
US7521435B2 (en) * 2005-02-18 2009-04-21 Pharma Diagnostics, N.V. Silicon containing compounds having selective COX-2 inhibitory activity and methods of making and using the same
WO2006121887A2 (en) * 2005-05-05 2006-11-16 Cook Biotech Incorporated Implantable materials and methods for inhibiting tissue adhesion formation
WO2006123242A1 (en) * 2005-05-18 2006-11-23 Pfizer Limited 1, 2, 4 -triazole derivatives as vasopressin antagonists
UA94979C2 (uk) 2006-12-22 2011-06-25 Рекордати Айеленд Лимитед КОМБІНОВАНА ТЕРАПІЯ ПОРУШЕНЬ НИЖНІХ СЕЧОВИВІДНИХ ШЛЯХІВ ЛІГАНДАМИ α2δ І НПЗП
JP2010529192A (ja) 2007-06-14 2010-08-26 アムゲン インコーポレイティッド ヒドロキシステロイドデヒドロゲナーゼの三環式阻害剤
US10842653B2 (en) 2007-09-19 2020-11-24 Ability Dynamics, Llc Vacuum system for a prosthetic foot
GB0903493D0 (en) 2009-02-27 2009-04-08 Vantia Ltd New compounds
CN102329280A (zh) * 2011-08-05 2012-01-25 上海大学 三氟甲基取代恶唑衍生物及其制备方法
CN102997862B (zh) * 2011-09-13 2015-12-16 上海汇众汽车制造有限公司 焊接熔深测量方法
US20240165148A1 (en) 2021-03-15 2024-05-23 Saul Yedgar Hyaluronic acid-conjugated dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (nsaids) for treating or alleviating inflammatory diseases

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3546342A (en) 1966-11-18 1970-12-08 Wyeth John & Brother Ltd Method of relieving inflammation by administration of 2,4 - diarylthiazole- 5 - alkanoic acids and derivatives thereof
GB1206403A (en) 1966-12-15 1970-09-23 Wyeth John & Brother Ltd Oxazoles
GB1145884A (en) 1966-11-18 1969-03-19 Wyeth John & Brother Ltd Thiazole derivatives
IE32084B1 (en) 1967-06-07 1973-04-04 Wyeth John & Brother Ltd Thiazole derivatives
FI53314C (fi) 1967-06-14 1978-04-10 Wyeth John & Brother Ltd Foerfarande foer framstaellning av farmaceutiskt anvaendbar 2-(fenyleller p-klorfenyl) oxazol-4-yl (aettiksyra -acetatsalt eller -acetamid)
US3901908A (en) * 1970-12-28 1975-08-26 Ciba Geigy Corp 2-alkyl- and 2-cycloalkyl-4,5-bis-phenyl-imidazoles
US4451171A (en) 1980-11-07 1984-05-29 Owens-Corning Fiberglas Corporation Polyamide as a primer for use with asphaltic membranes
US4451471A (en) 1981-03-18 1984-05-29 Ciba-Geigy Corporation Certain 2,4,5-tri-substituted thiazoles, pharmaceutical compositions containing same and methods of using same
GB2123831B (en) 1981-07-20 1986-01-15 Ciba Geigy Ag Trisubstituted oxazo compounds
JPS59500054A (ja) 1982-01-22 1984-01-12 チバ・ガイギ−・アクチエンゲゼルシヤフト 三置換オキサザ化合物
JPS59500055A (ja) 1982-01-25 1984-01-12 チバ・ガイギ−・アクチエンゲゼルシヤフト 三置換ジアザ誘導体
EP0117578A3 (de) * 1983-02-23 1985-01-30 Shionogi & Co., Ltd. Azol-substituierte Alkoholderivate
JPS59155365A (ja) * 1983-02-23 1984-09-04 Shionogi & Co Ltd ２−ヒドロキシプロピオフエノン誘導体
JPS6058981A (ja) 1983-09-09 1985-04-05 Takeda Chem Ind Ltd ５−ピリジル−１，３−チアゾ−ル誘導体，その製造法およびそれを含んでなる医薬組成物
DE3486009T2 (de) 1983-09-09 1993-04-15 Takeda Chemical Industries Ltd 5-pyridyl-1,3-thiazol-derivate, ihre herstellung und anwendung.
US4632930A (en) 1984-11-30 1986-12-30 E. I. Du Pont De Nemours And Company Antihypertensive alkyl-arylimidazole, thiazole and oxazole derivatives
US4782058A (en) * 1985-04-26 1988-11-01 Pennwalt Corporation 1,3,4,6,7,11b-Hexahydro-6-phenyl-2H-pyrazino-(2,1-a)isoquinolines, for anti-histamine or anti-depression treatment
JPS62138485A (ja) * 1985-12-02 1987-06-22 チバ−ガイギ−　アクチエンゲゼルシヤフト 除草及び植物生長調節組成物
US4849007A (en) * 1985-12-02 1989-07-18 Ciba-Geigy Corporation Herbicidal epoxides
IL83467A0 (en) 1986-08-15 1988-01-31 Fujisawa Pharmaceutical Co Imidazole derivatives,processes for their preparation and pharmaceutical compositions containing the same
JPH0283372A (ja) 1988-09-19 1990-03-23 Taisho Pharmaceut Co Ltd シクロヘキシルイミダゾール誘導体
PH27357A (en) 1989-09-22 1993-06-21 Fujisawa Pharmaceutical Co Pyrazole derivatives and pharmaceutical compositions comprising the same
JPH03116048A (ja) * 1989-09-29 1991-05-17 Toshiba Corp 感光性組成物
JPH03208056A (ja) * 1990-01-11 1991-09-11 Toshiba Corp 感光性組成物
GB9012936D0 (en) 1990-06-11 1990-08-01 Fujisawa Pharmaceutical Co Thiophene derivatives,processes for preparation thereof and pharmaceutical composition comprising the same
JPH0545883A (ja) * 1991-03-26 1993-02-26 Toshiba Corp 感光性組成物
JPH0570446A (ja) 1991-09-13 1993-03-23 Taisho Pharmaceut Co Ltd Ｎ−チアゾリルスルホンアミド誘導体
US5541080A (en) * 1991-11-01 1996-07-30 Wisconsin Alumni Research Fdn. Method for preparing L-alpha-amino acids
US5219731A (en) * 1991-11-01 1993-06-15 Wisconsin Alumni Research Foundation Method for preparing optically-active amino acid derivatives
JP3116048B2 (ja) 1991-11-09 2000-12-11 ローム株式会社 強誘電体層を有する半導体素子及びその製法
JP3141261B2 (ja) 1992-10-22 2001-03-05 松下電工株式会社 警報表示器
CA2152792C (en) 1993-01-15 2000-02-15 Stephen R. Bertenshaw Novel 3,4-diaryl thiophenes and analogs thereof having use as antiinflammatory agents
CA2161789A1 (en) 1993-05-13 1994-11-24 Jacques Yves Gauthier 2-substituted-3,4-diarylthiophene derivatives as inhibitors of cyclooxygenase
US6090834A (en) 1993-05-21 2000-07-18 G.D. Searle & Co. Substituted oxazoles for the treatment of inflammation
US5380738A (en) * 1993-05-21 1995-01-10 Monsanto Company 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
JP2636819B2 (ja) * 1994-12-20 1997-07-30 日本たばこ産業株式会社 オキサゾール系複素環式芳香族化合物
WO1996036617A1 (en) 1995-05-19 1996-11-21 G.D. Searle & Co. Substituted oxazoles for the treatment of inflammation
JP3208056B2 (ja) 1996-01-29 2001-09-10 株式会社ノリタケカンパニーリミテド 複合材料のポリシング加工方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8247423B2 (en) 2007-07-12 2012-08-21 Tragara Pharmaceuticals, Inc. Methods and compositions for the treatment of cancer, tumors, and tumor-related disorders

Also Published As

Publication number Publication date
TW403742B (en) 2000-09-01
US20020107270A1 (en) 2002-08-08
ATE180253T1 (de) 1999-06-15
CN1146204A (zh) 1997-03-26
US6362209B1 (en) 2002-03-26
CA2183645A1 (en) 1996-06-27
CZ285476B6 (cs) 1999-08-11
CZ274996A3 (en) 1996-12-11
SK117596A3 (en) 1997-05-07
DK0745596T3 (da) 1999-11-08
NO963450L (no) 1996-10-04
NO963450D0 (no) 1996-08-19
JPH0952882A (ja) 1997-02-25
AU695045B2 (en) 1998-08-06
HU9602576D0 (en) 1996-11-28
HUT76541A (en) 1997-09-29
DE69509753D1 (de) 1999-06-24
SK281468B6 (sk) 2001-04-09
US20020143040A1 (en) 2002-10-03
GR3030643T3 (en) 1999-10-29
ES2132751T3 (es) 1999-08-16
US5994381A (en) 1999-11-30
WO1996019463A1 (fr) 1996-06-27
DE69509753T2 (de) 1999-12-02
EP0745596A1 (de) 1996-12-04
FI963238A0 (fi) 1996-08-19
NZ297105A (en) 1997-09-22
JP2636819B2 (ja) 1997-07-30
US20020198245A1 (en) 2002-12-26
AU4189796A (en) 1996-07-10
MX9603506A (es) 1997-03-29
EP0745596A4 (de) 1997-05-02
BR9506815A (pt) 1997-09-09
FI963238A (fi) 1996-10-17
CA2341921A1 (en) 1996-06-27
KR100201581B1 (ko) 1999-06-15
US20020115701A1 (en) 2002-08-22
US20020107271A1 (en) 2002-08-08
US20020198244A1 (en) 2002-12-26
NO306778B1 (no) 1999-12-20

Similar Documents

Publication Publication Date Title
EP0745596B1 (de) Hetero aromatische oxazole und deren verwendung
US6002014A (en) Oxazole derivatives and use thereof
JP2512751B2 (ja) 薬理学的に活性な１，５−ジアリ−ル−３−置換−ピラゾ−ル類およびそれらを製造する方法
JP2007197324A (ja) ２，４，５−置換−１，３−アゾール誘導体
WO1999020309A1 (fr) Agonistes de l'acide retinoique, agents preventifs et therapeutiques des nephrites
FR2665440A1 (fr) Nouveaux cycloalkylsulfonamides substitues, procedes de preparation et medicaments les contenant.
AU729453B2 (en) Novel carbocyclic diarylmethylene derivatives, methods for preparing same, and therapeutical uses thereof
IE60015B1 (en) Antiallergy and antiinflammatory agents
US5116855A (en) Rhodanine derivatives and pharmaceutical compositions
WO1990005132A1 (en) Substituted allylamine derivatives, process for their preparation and their use
JPH0374375A (ja) 抗炎症剤としてのフエナメート１，３，４‐チアジアゾール類および１，３，４‐オキサジアゾール類
US5571825A (en) Method of selectively inhibiting prostaglandin G/H synthase-2
JPH10509140A (ja) ピラゾール誘導体
CA1299577C (en) Tetrahydrocarbazole 1-alkanoic acids
KR20000005146A (ko) 퓨란 디아릴메틸리덴 유도체, 이의 제조방법 및이를 함유하는약제학적 조성물
KR20020087942A (ko) 항염증 활성이 있는 신규 이미다졸 유도체
US5843999A (en) 2-phenylazulene derivatives and a manufacturing method of these compounds
KR960008245B1 (ko) 로다닌 유도체 및 약제학적 조성물
CA2022460A1 (fr) Derives benzothiaziniques, leur preparation et leurs applications comme medicaments ou comme intermediaires de synthese de medicaments
WO1993013057A1 (en) Substituted benzenesulfonamide derivative

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19960814

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI NL PT SE

A4 Supplementary search report drawn up and despatched
AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI NL PT SE

17Q First examination report despatched

Effective date: 19970603

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI NL PT SE

REF Corresponds to:

Ref document number: 180253

Country of ref document: AT

Date of ref document: 19990615

Kind code of ref document: T

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 69509753

Country of ref document: DE

Date of ref document: 19990624

ET Fr: translation filed
REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: A. BRAUN, BRAUN, HERITIER, ESCHMANN AG PATENTANWAE

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2132751

Country of ref document: ES

Kind code of ref document: T3

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 19990624

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20021108

Year of fee payment: 8

Ref country code: PT

Payment date: 20021108

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20021112

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20021113

Year of fee payment: 8

Ref country code: AT

Payment date: 20021113

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 20021125

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20021127

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20021204

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20021218

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20021231

Year of fee payment: 8

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20031218

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20031218

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20031219

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20031219

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20031231

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20031231

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20031231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040102

BERE Be: lapsed

Owner name: JAPAN *TOBACCO INC.

Effective date: 20031231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040701

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040705

EUG Se: european patent has lapsed
REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee

Effective date: 20040701

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: PT

Ref legal event code: MM4A

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 20040630

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20041210

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20041215

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20041227

Year of fee payment: 10

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20031219

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.

Effective date: 20051218

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20051218

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060701

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20051218

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060831

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20060831